Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abciximab + reteplase
- Development stage
- Unknown
- Lead developer
- Janssen Biotech
- Modality
- Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Abciximab + reteplase is a combination therapy used for reperfusion in patients with ST-segment elevation myocardial infarction (STEMI). This regimen combines full-dose abciximab (a glycoprotein IIb/IIIa inhibitor) with reduced-dose reteplase (a thrombolytic agent). The combination has shown improved reperfusion rates and beneficial effects on inflammatory myocardial response compared to standard thrombolytic therapy alone, though it has not demonstrated significant reduction in 30-day mortality. It is associated with fewer complications of acute MI including reduced rates of reinfarction and recurrent ischemia.
- Brand names
- ReoPro + Retavase
- Other names
- reteplase plus abciximabr-PA + abciximabcombination reteplase/abciximab
02
Targets
GPIIb/IIIa (Integrin alpha-IIb/beta-3)αMβ2 (Integrin αMβ2)Fibrin (Factor Ia)PLG (Plasminogen)αVβ3 (Integrin αVβ3)
Beyond the preview
Go deeper on abciximab + reteplase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abciximab + reteplase.